AIA Group Ltd lifted its holdings in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 441.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 145,150 shares of the company's stock after buying an additional 118,357 shares during the quarter. AIA Group Ltd's holdings in Dr. Reddy's Laboratories were worth $2,292,000 as of its most recent SEC filing.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. Robeco Institutional Asset Management B.V. raised its stake in Dr. Reddy's Laboratories by 453.8% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock valued at $180,620,000 after purchasing an additional 9,373,412 shares during the last quarter. Aikya Investment Management Ltd grew its position in Dr. Reddy's Laboratories by 416.1% in the fourth quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock worth $88,590,000 after acquiring an additional 4,523,303 shares during the period. Vanguard Group Inc. increased its stake in Dr. Reddy's Laboratories by 397.2% during the fourth quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock worth $77,311,000 after acquiring an additional 3,911,404 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Dr. Reddy's Laboratories by 462.1% in the 4th quarter. JPMorgan Chase & Co. now owns 2,814,710 shares of the company's stock valued at $44,444,000 after buying an additional 2,313,987 shares during the period. Finally, Fisher Asset Management LLC boosted its stake in Dr. Reddy's Laboratories by 402.5% during the fourth quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company's stock worth $38,981,000 after buying an additional 1,977,419 shares during the period. Institutional investors and hedge funds own 3.85% of the company's stock.
Dr. Reddy's Laboratories Stock Performance
Shares of RDY stock traded up $0.09 during mid-day trading on Wednesday, hitting $13.25. 1,364,777 shares of the stock were exchanged, compared to its average volume of 1,327,829. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. The stock has a market capitalization of $11.06 billion, a price-to-earnings ratio of 21.10 and a beta of 0.48. The stock's fifty day simple moving average is $13.38 and its two-hundred day simple moving average is $14.55. Dr. Reddy's Laboratories Limited has a 12-month low of $12.50 and a 12-month high of $16.89.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, analysts forecast that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of brokerages have recently weighed in on RDY. Nomura cut Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research note on Thursday, December 19th. StockNews.com lowered Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a report on Friday, December 6th.
Check Out Our Latest Stock Analysis on RDY
Dr. Reddy's Laboratories Profile
(
Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Featured Stories
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
